COMMUNIQUÉS West-GlobeNewswire

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
10/11/2025
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required [...]
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/11/2025
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
10/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)- [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Third Quarter 2025 Financial Results on November 14, 2025
10/11/2025
FREDERICK, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Burn Blend 2025 | Effective Weight Loss Supplement Read Benefits, Ingredients Lunch Burn Blend Canada & Australia
10/11/2025
Burn Blend is a natural Weight Loss Supplement that combines nature’s most effective ingredients to support focus, endurance, and metabolism. Read BurnBlend consumer reports. New York City, Nov. 10, 2025 (GLOBE NEWSWIRE [...]
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11/2025
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Glaucoma 360 2026: Where Science, Innovation, and Collaboration Shape the Future of Vision
10/11/2025
Annual event accelerates progress toward curing glaucoma, from groundbreaking research to emerging therapies SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation (GRF) today announced the 15th [...]
HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy
10/11/2025
Washington, D.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services (HHS) today announced historic action to restore gold-standard science to women’s health. After more than two decades [...]
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
10/11/2025
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel [...]
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
10/11/2025
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
10/11/2025
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated [...]
NeXtGen Biologics and Lovell® Government Services Partner to Bring Innovative Advanced Wound Care Technology to Federal Healthcare Systems
10/11/2025
PENSACOLA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lovell ® Government Services and NeXtGen™ Biologics, Inc., a medical device company that manufactures NeoMatriX ® , announced today that they have partnered to serve [...]
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
10/11/2025
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare [...]
Voyager Reports Third Quarter 2025 Financial and Operating Results
10/11/2025
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small [...]
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
10/11/2025
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates [...]
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
10/11/2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
10/11/2025
ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device. HOPE is one of the first Ampa deployments nationwide and is now [...]
Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
10/11/2025
GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
10/11/2025
Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]

Pages